

# Ophthalmologic findings in Gaucher's disease type III: case report

## *Achados oftalmológicos na doença de Gaucher tipo III: caso clínico.*

---

Alexis Galeno Matos<sup>1</sup>, Viviane Pinho Gurgel<sup>1</sup>, Mariana Caliope Gonçalves<sup>2</sup>

### **ABSTRACT**

*We report a case of a patient with Gaucher's disease type III, with mutation in Exon9, 1246G>A and 1251G>C, seeking to investigate the suspected glaucoma, to describe the ophthalmological findings, as glycolipid accumulation in the pre-retinal region and to investigate the possible correlation with the decrease of the layer of nerve fibers.*

**Keywords:** Gaucher disease; Glaucoma; Eye manifestations; Case reports

### **RESUMO**

Relata-se um caso de uma paciente com doença de Gaucher tipo III, com mutação no Exon9, 1246G>A e 1251G>C, buscando investigar a suspeita de glaucoma, descrever os achados oftalmológicos, como acúmulo de glicolípido em região pré-retiniana e investigar a possível correlação com a diminuição da camada de fibras nervosas.

**Descritores:** Doença de Gaucher; Glaucoma; Manifestações oculares; Relatos de casos

---

<sup>1</sup> Fundação Leiria de Andrade, Fortaleza, CE, Fortaleza.

<sup>2</sup> Specialization Course in Ophthalmology, Fundação Leiria de Andrade, Fortaleza, CE, Fortaleza.

**The authors declare no conflicts of interests.**

Received for publication 15/08/2017 - Accepted for publication 24/09/2017.

## INTRODUCTION

**G**aucher's disease (GD) is an autosomal recessive genetic disorder caused by mutations located in the arm 1q21 responsible for encoding the acidic  $\beta$ -glucosidase enzyme, also called glucocerebrosidase (GC).<sup>(1)</sup>

GC is a lysosomal enzyme that in macrophages helps to metabolize the glucocerebroside called glycosylceramide, a glycolipid originated from the decomposition of the membrane of red blood cells and leukocytes.<sup>(1)</sup>

GC deficiency causes glucocerebroside accumulation in macrophages, also called Gaucher's cells, and the main implications are in the spleen, liver, bone marrow, bones and lungs. The most common symptoms are hepatosplenomegaly, anemia, thrombocytopenia, and bone pain.<sup>(2)</sup>

Diagnosis can be made by detecting Gaucher's cells in tissues, or by measuring the activities of GC in leukocytes or in fibroblasts culture, or by molecular analysis.<sup>(1,2,3)</sup>

Ocular manifestations include oculomotor apraxia and supranuclear abnormalities, mainly type II and III. Intraocular manifestations include corneal opacification and pinguecula, cherry macula, and retinal lesions typical of the pre-retinal accumulation of glycolipid.<sup>(4,5)</sup> The incidence of vitreous opacities is approximately 3% in a series of 80 cases of Gaucher's type I.<sup>(6)</sup>

Tabuleiro do Norte (TN), located in eastern Ceará, has the highest prevalence of GD in Brazil (1:4,000 inhabitants).<sup>(7)</sup> It is speculated that this may be due to the low rate of migration, the high level of inbreeding over many generations, and the possible influence of the Jewish origin of some local families who came from Portugal to the Northeast Region of Brazil due to the wars against the Dutch in the second half of the seventeenth century.<sup>(8)</sup>

## CASE REPORT

GKMA, 29, female, from Tabuleiro do Norte - Ceará, Gaucher's disease type III patient with mutation in Exon9, 1246G>A and 1251G>C and enzymatic beta-glucosidase and chitotriosidase positive assays for Gaucher's, in use of Miglustat®, Depakot® and phenobarbital. She denies trauma, ophthalmologic surgeries, or chronic use of corticosteroids.

She reported frequent seizures during childhood. She was referred to evaluate suspected glaucoma presenting corrected visual acuity in the right eye 20/25 (2.25 -1.50 at 100°) and in the left eye 20/25 (-3.00 -0.50 at 5°). Eye movement had no restrictions or changes. No significant corneal or conjunctival changes were identified in biomicroscopy. Aplanation tonometry at 9:30 of 14 mmHg in both eyes. Pachymetry was normal, close to 530 microns, and open angle gonioscopy had normal pigmentation in both eyes.

In funduscopy there was a significant increase of excavations in the right eye 0.8H x 0.9V (Figure 1) and in the left eye 0.8H x 0.8V (Figure 2), and both eyes showed white point deposits in the perimacular region and on average retinal periphery. Such deposits in the analysis of optical coherence tomography were shown in pre-retinal location (Figure 3), and the nerve fiber layer was densely diminished in both eyes (Figure 4), characterizing glaucomatous neuropathy.

As a result of frequent myoclonic movements, the patient was not able to make the campimetry exam.



Figure 1: Retinography of the right eye



Figure 2: Retinography of the left eye





Figure 3: Optic coherence tomography showing deposition in the pre-retinal region



**Figure 4:** Optical coherence tomography demonstrating a decrease in the layer of nerve fibers in both eyes

## DISCUSSION

Gaucher's disease is autosomal recessive due to the deficiency of the beta glucosidase enzyme by mutation in the gene 1q21, promoting the accumulation of glucosylceramide in the cells of the reticuloendothelial system, with type III being characterized by neuropathic affection and myoclonic epilepsy.

Ophthalmologically, it is characterized by cherry macula and accumulation of points of typical preretinal white matter, by probable accumulation of higher levels of glucosylceramide, presented by the patient studied.

Glaucoma is not a finding described in the literature in Gaucher's disease. Some authors suggest that thinning of the nerve fiber layer of the retina is due to loss of the enzymatic activity of glucocerebrosidase associated to oxidative stress and mitochondrial dysfunction.<sup>(9)</sup> Gaucher's disease has also been correlated to the increased risk for Parkinson's, corroborating with the disease's influence on nerve cells.<sup>(10)</sup>

The correlation between glaucoma and Gaucher's disease was considered by Orwin in his dissertation by the mutation in the myocillin gene altering the protein conformation, as well as the  $\beta$ -glucosidase in DG.<sup>(11)</sup>

In the present case, the patient with Gaucher's disease type III had pre-retinal lesions from the deposit, and a marked decrease in the retinal fiber layer and increased excavations. However, she didn't present high intraocular pressure, which could lead to a diagnosis of glaucoma of normal pressure or a nervous degeneration not related to intraocular pressure, without the need for hypotensive treatment.

## REFERENCES

1. Beutler E, Grabowski G (2001) Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3635–3668
2. Beutler E, Saven A. Misuse of marrow examination in the diagnosis of Gaucher disease. *Blood*. 1990;76(3):646-8.
3. Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, Scott CR, Wappner RS, Weinreb NJ, Wisch JS. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. *Arch Intern Med*. 1998 ;158(16):1754-60. Review.
4. Cogan DG, Chu FC, Gittinger J, Tychsens L. Fundal abnormalities of Gaucher's disease. *Arch Ophthalmol*. 1980;98(12):2202-3.
5. Abrahamov A, Elstein D, Gross-Tsur V, Farber B, Glaser Y, Hadas-Halpern I, et al. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. *Lancet*. 1995;346(8981):1000-3.
6. Hsing YE, Foster A. Preretinal and posterior vitreous deposits in Gaucher disease. *JAMA Ophthalmol*. 2014;132(8):992.
7. Chaves RG, Coelho JC, Michelin-Tirelli K, Maurício TF, de Freitas Maia Chaves E, de Almeida PC, et al. Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study. *JIMD Rep*. 2011;1:73-8.
8. Chaves RG. Rastreamento populacional para Doença de Gaucher em Tabuleiro do Norte-CE [tese]. Natal: Universidade Federal do Rio Grande do Norte; 2011.
9. McNeill A, Roberti G, Lascaratos G, Hughes D, Mehta A, Garway-Heath DF, et al. Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. *Mol Genet Metab*. 2013;109(2):221-3.
10. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. *JAMA Neurol*. 2014;71(6):752-757.
11. Orwig SD. Biophysical and structural characterization of proteins implicated in glaucoma and Gaucher disease [dissertation]. Georgia: Georgia Institute of Technology; 2011.

### Corresponding author:

Alexis G. Matos  
Hospital de Olhos Leiria de Andrade  
Rua Rocha Lima, 1140 – Fortaleza, CE, Brazil.  
Phone N<sup>o</sup>.: +55.85.3266-5511  
Mobile: +55.85.99685-2005  
E-mail: alexisgaleno@gmail.com